Facts of the Case
The Association for Molecular Pathology along with several other medical associations, doctors and patients sued the United States Patent and Trademark Office (USPTO) and Myriad Genetics to challenge several patents related to human genetics. The patents cover the BRCA1 and BRCA2 genes and certain mutations that indicate a high risk of developing breast cancer. The suit also challenged several method patents covering diagnostic screening for the genes. Myriad argued that once a gene is isolated, and therefore distinguishable from other genes, it could be patented. By patenting the genes, Myriad had exclusive control over diagnostic testing and further scientific research for the BRCA genes. Petitioners argued that patenting those genes violated §101 the Patent Act because they were products of nature. They also argued that the patents limit scientific progress. §101 limits patents to "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof."
The district court granted summary judgment in favor of petitioners, holding that isolating a gene does not alter its naturally occurring fundamental qualities. The U.S. Court of Appeals for the Federal Circuit reversed, holding that isolated genes are chemically distinct from their natural state in the human body. In March 2012, Petitioners sought certiorari; the U.S. Supreme Court vacated the Federal Circuit judgment and remanded for further consideration in light of Mayo Collective Services v. Prometheus Laboratories. On remand, the Federal Circuit again upheld the patentability of the BRCA genes.
Questions
Does §101 of the Patent Act allow patents on human genes?
Conclusions
-
Yes and no. Justice Clarence Thomas delivered the opinion for the 9-0 majority. The Supreme Court held that naturally occurring gene sequences, and their natural derivative products, are not patent eligible. Under §101 of the Patent Act, the discovery of natural products does not warrant a patent. However, the Court also held that the creation of a new product in a lab exempts that product from being a product of nature. Therefore, gene sequences refined by synthetic processes to create molecules that do not occur naturally are patent eligible.
Ten Years On: The America Invents Act and the role of the Patent Trial and Appeal Board in resolving patent disputes
On September 16, 2011, President Obama signed the American Invents Act (AIA) into law. The...
Originalism and Changes in Technology
2019 National Lawyers Convention
On November 14, 2019, the Federalist Society's Intellectual Property Practice Group hosted a panel for...
Should Congress Amend Section 101 of the Patent Act?
Intellectual Property Practice Group
This Teleforum addresses whether there is a need to amend Section 101 of the Patent...
Supreme Court Preview: What Is in Store for October Term 2013?
Co-sponsored by the Practice Groups and the Faculty Division
October 7th will mark the first day of the 2013 Supreme Court term. Thus far,...
2013 Annual Supreme Court Round Up
Washington, DC Lawyers Chapter
On July 8, 2013, Miguel Estrada of Gibson Dunn & Crutcher LLP delivered the Annual Supreme...
Patenting Human DNA: The Court's Decision - Podcast
Intellectual Property Practice Group Podcast
To listen, please right click on the audio file you wish to hear and then...
Association for Molecular Pathology v. Myriad Genetics, Inc. - Post-Decision SCOTUScast
SCOTUScast 6-19-13 featuring Gregory Dolin
On June 13, 2013, the Supreme Court announced its decision in Association for Molecular Pathology v....
DNA and Patents: Association for Molecular Pathology v. Myriad Genetics, Inc. - Podcast
Intellectual Property Practice Group Podcast
On Monday, April 15, the Supreme Court heard oral argument in a patents case, Association for...
Association for Molecular Pathology v. Myriad Genetics - Post-Argument SCOTUScast
SCOTUScast 4-30-13 featuring Gregory Dolin
On April 15, 2013, the Supreme Court heard oral argument in Association for Molecular Pathology v....
Intellectual Property: Undermining or Preserving Property Rights? The New Administrative Patents
2012 National Lawyers Convention
The Intellectual Property Practice Group hosted this panel on "Undermining or Preserving Property Rights? The...
Mayo Collaborative Services v. Prometheus Laboratories, Inc. - Post-Decision SCOTUScast
SCOTUScast 03-26-12 featuring Adam Mossoff
On March 20, 2012 the Supreme Court announced its decision in Mayo Collaborative Services v. Prometheus...